ALLMedicine™ Congenital Hyperinsulinism Center

May 20th, 2022 - Congenital hyperinsulinism (HI) results in severe, persistent hypoglycemia and is associated with high risk of neurodevelopmental deficits. Sixty percent of HI cases are unresponsive to diazoxide, the only FDA-approved drug. Somatostatin analogs a...

May 5th, 2022 - This study aimed to assess mental health, family burden, and quality of life (PQoL) in parents of children with persistent congenital hyperinsulinism (CHI). Forty-eight individual CHI parents (75% female) completed self-reported questionnaires and...

Apr 14th, 2022 - The aim of this study was to assess whether exendin-(9-39) will increase fasting and postprandial plasma glucose and decrease the incidence of hypoglycemia in children with hyperinsulinism (HI). This was an open-label, four-period crossover study....

Apr 1st, 2022 - The objective of the trial is to evaluate the efficacy of dasiglucagon in reducing glucose requirements in children with persistent congenital hyperinsulinism (CHI) requiring continuous intravenous (IV) glucose administration to prevent/manage hyp...

Mar 17th, 2022 - Hyperinsulinism results from inappropriate insulin secretion during hypoglycaemia. Down syndrome is causally linked to a number of endocrine disorders including Type 1 diabetes and neonatal diabetes. We noted a high number of individuals with Down...

Apr 1st, 2022 - The objective of the trial is to evaluate the efficacy of dasiglucagon in reducing glucose requirements in children with persistent congenital hyperinsulinism (CHI) requiring continuous intravenous (IV) glucose administration to prevent/manage hyp...

Jan 25th, 2022 - There is a significant unmet medical need to develop new therapies aimed at preventing chronic recurrent hypoglycemia in congenital HI, the most common cause of persistent hypoglycemia in children. RZ358 is a human mAb that allosterically attenuat...

Jan 10th, 2022 - Single centre prospective cohort phase III study of 18F-DOPA PET/CT imaging in specific patient populations: Pediatric patients with congenital hyperinsulinism Pediatric patients with neuroblastoma Pediatric or Adult patients with suspected extra-...

Oct 22nd, 2021 - Congenital hyperinsulinism (CHI) is a clinically and genetically heterogeneous disorder that is the most common cause of permanent hypoglycemia in infants and children. More than 50% of the medically-unresponsive patients have focal disease. Which...

Mar 13th, 2020 - This is a placebo controlled study with randomized crossover design to evaluate the effect of the glucagon-like peptide-1 (GLP-1) receptor antagonist, exendin-(9-39), on fasting blood glucose levels, protein-induced hypoglycemia, and fasting toler...

Apr 21st, 2022 - An investigational glucagon-like peptide-1 (GLP-1) antagonist, exendin-(9-39), prevents fasting and protein-induced hypoglycemia among children with congenital hyperinsulinism, new data suggest.   Results from the open-label crossover phase 2 tria...

Mar 22nd, 2022 - Children who experienced low blood sugar as newborns did not have different academic performance results 10 years later compared with those who did not have hypoglycemia, new results from the CHYLD study suggest, conflicting with previous findings...

Nov 13th, 2019 - EPI is characterized by a deficiency of the above mentioned exocrine pancreatic enzymes, which results in an inability to digest food properly (maldigestion). Because pancreatic lipase accounts for up to 90% of fat digestion, maldigestion of fat i...

Apr 12th, 2019 - The International Pediatric Association biennial meeting has long focused on the terrifying list of threats to child health: poverty, malnutrition, vaccine-preventable disease, toxic stress. But this year's meeting, held in Panama City, Panama, Ma...

Sep 27th, 2017 - Popular late-night TV talk show host Conan O’Brien will host the 2017 “Sugar Soiree” in New York City on November 19, 2017, to be sponsored by Congenital Hyperinsulinism International. This annual event is a fundraiser for programs to benefit thos.